MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate various intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Key demo aims were being To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, though among the exploratory ... https://px-47821098.pages10.com/bcat-in-4-secrets-66381864